Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

Affiliations

• ¹ Department of Hematology, Oncology and Tumor Immunology, CVK, Charité-Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. thomas.burmeister@charite.de.
• ² University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.
• ³ Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany.
• ⁴ Diagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe University, Frankfurt, Germany.
• ⁵ Department of Hematology, Oncology and Tumor Immunology, CBF, Charité Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
• ⁶ Department of Medicine II, Goethe University, University Hospital, Frankfurt, Germany.
• ⁷ University Hospital Erlangen, Department of Internal Medicine 5, Hematology and Oncology, Erlangen, Germany.
• ⁸ Department of Hematology and Oncology, Otto-von-Guericke University Hospital, Magdeburg, Germany.
• ⁹ Department of Hematology, Oncology, University Hospital, Halle/Saale, Germany.
• ¹⁰ Department of Hematology, Oncology and Tumor Immunology, CVK, Charité-Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
• ¹¹ Department of Hematology, Oncology, University Hospital of Düsseldorf, Düsseldorf, Germany.
• ¹² Department of Hematology, Oncology, University Hospital Ulm, Ulm, Germany.
• ¹³ Department of Hematology, Oncology, University Hospital Würzburg, Würzburg, Germany.